Wilmington, NC-September 15, 2009
PPD, Inc. has opened its global central lab facility in Singapore.
The laboratory instrumentation and standards in Singapore are identical to platforms located at PPD's global central labs in Brussels, Belgium; Highland Heights, Ky.; and Beijing, China. Assays are extensively cross validated among all PPD locations to produce combinable data. The Singapore lab interfaces directly with ConneXion, the company's proprietary single global database. Clients can view and analyze laboratory results from all lab locations using PPD Clicks˙, a secure Web site launched last year.
PPD also has an office in Singapore where for more than 10 years it has provided a range of clinical development services, including clinical trial management and monitoring, patient recruitment, site identification and regulatory affairs.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Vabysmo Shows Significant Vision Improvement for Diabetic Macular Edema in Underrepresented Patients
October 22nd 2024Phase IV ELEVATUM trial results show that one year of treatment with Vabysmo significantly improved vision in underrepresented racial and ethnic groups with diabetic macular edema, supporting the drug's efficacy and safety across diverse populations.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Clesrovimab Shows Significant Reduction in RSV Infections, Hospitalizations in Infants
October 18th 2024Merck's investigational monoclonal antibody, clesrovimab, shows significant efficacy in reducing respiratory syncytial virus-related infections and hospitalizations in infants, with a favorable safety profile.